New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy reduced the risk of BARC type 2, 3 or 5 bleeding in high-bleed-risk patients who underwent percutaneous coronary intervention (PCI) and completed three months of dual antiplatelet therapy (DAPT) at 12 months. Brilinta monotherapy (90 mg twice daily) was compared to Brilinta plus low-dose aspirin.

Cardiac magnetic resonance imaging (MRI) analysis can be performed significantly faster with similar precision to experts when using automated machine learning, according to new research. The study was published in Circulation: Cardiovascular Imaging, an American Heart Association journal.

Abbott announced approvals in Europe for two of its pediatric devices — the Masters HP 15mm rotatable mechanical heart valve and the Amplatzer Piccolo Occluder. Both devices have received CE Mark and are now available in Europe and other countries that recognize CE Mark. The new treatments, already available in the U.S., offer young pediatric patients and their families hope when no other suitable treatment option may exist.

Orchestra BioMed Inc., in partnership with Terumo Corp. announced the company has secured Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its Virtue Sirolimus-Eluting Balloon (SEB) in the treatment of below-the-knee (BTK) peripheral artery disease.

Low-dose aspirin does not prolong disability-free survival of healthy people over 70, even in those at the highest risk of cardiovascular disease. The late-breaking results of the ASPREE trial were presented at the European Society of Cardiology (ESC) Congress 2019 together with the World Congress of Cardiology, Aug. 31-Sept. 4 in Paris. France.

Discharge of patients with suspected acute coronary syndromes under a 0- and 1-hour high-sensitivity cardiac troponin T (hs-cTnT) protocol is safe, according to recent research. The late-breaking results from the RAPID-TnT trial were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2019, Aug. 31-Sept. 4 in Paris, France, together with the World Congress of Cardiology and published in Circulation.[1] The trial also found that better strategies are needed to optimize outcomes in patients newly diagnosed with modest troponin elevations.

The European Society of Cardiology (ESC) published new guidelines on the diagnosis and management of chronic coronary syndromes (CCS), which classifies computed tomography angiography (CTA) as a Class 1 recommendation for diagnosing CAD in symptomatic patients. The document, which is a continuation of the 2013 stable coronary artery disease (CAD) guidelines, updates the term to CCS to emphasize the dynamic nature of the disease. It was released at the 2019 ESC Congress, Aug. 31-Sept. 4 in Paris, France, and published simultaneously in the European Heart Journal.